vs
安捷伦科技（A）与RYTHM, Inc.（RYM）财务数据对比。点击上方公司名可切换其他公司
安捷伦科技的季度营收约是RYTHM, Inc.的168.7倍（$1.8B vs $10.7M）。安捷伦科技净利率更高（17.0% vs -127.6%，领先144.6%）。RYTHM, Inc.同比增速更快（242.0% vs 7.0%）。过去两年RYTHM, Inc.的营收复合增速更高（102.6% vs 6.9%）
安捷伦科技是全球知名的生命科学、诊断与应用化学领域解决方案提供商，旗下生命科学与应用市场业务板块提供液相色谱系统及组件、液相色谱质谱联用系统、气相色谱设备、电感耦合等离子体质谱仪、原子吸收仪等多种分析检测仪器，服务全球各领域客户。
RYTHM Inc.是一家临床阶段生物制药企业，专注于研发和商业化针对罕见遗传性内分泌与代谢疾病的创新疗法，主要面向美国市场，服务存在未被满足医疗需求的儿童及成人患者群体。
A vs RYM — 直观对比
营收规模更大
A
是对方的168.7倍
$10.7M
营收增速更快
RYM
高出235.0%
7.0%
净利率更高
A
高出144.6%
-127.6%
两年增速更快
RYM
近两年复合增速
6.9%
损益表 — Q1 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $1.8B | $10.7M |
| 净利润 | $305.0M | $-13.6M |
| 毛利率 | 52.6% | 75.5% |
| 营业利润率 | 19.6% | -121.5% |
| 净利率 | 17.0% | -127.6% |
| 营收同比 | 7.0% | 242.0% |
| 净利润同比 | -4.1% | 44.1% |
| 每股收益（稀释后） | $1.07 | $-6.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ARYM
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.9B | $10.7M | ||
| Q3 25 | $1.7B | $4.0M | ||
| Q2 25 | $1.7B | $2.0M | ||
| Q1 25 | $1.7B | $538.0K | ||
| Q4 24 | $1.7B | $-7.5M | ||
| Q3 24 | $1.6B | $1.9M | ||
| Q2 24 | $1.6B | $3.0M |
净利润ARYM
| Q1 26 | $305.0M | — | ||
| Q4 25 | $434.0M | $-13.6M | ||
| Q3 25 | $336.0M | $-10.7M | ||
| Q2 25 | $215.0M | $-7.4M | ||
| Q1 25 | $318.0M | $-1.6M | ||
| Q4 24 | $351.0M | $-24.4M | ||
| Q3 24 | $282.0M | $-18.7M | ||
| Q2 24 | $308.0M | $-3.0M |
毛利率ARYM
| Q1 26 | 52.6% | — | ||
| Q4 25 | 53.2% | 75.5% | ||
| Q3 25 | 51.1% | 34.0% | ||
| Q2 25 | 51.9% | 33.4% | ||
| Q1 25 | 53.5% | 16.7% | ||
| Q4 24 | 53.9% | — | ||
| Q3 24 | 54.2% | 11.6% | ||
| Q2 24 | 54.4% | 37.6% |
营业利润率ARYM
| Q1 26 | 19.6% | — | ||
| Q4 25 | 23.8% | -121.5% | ||
| Q3 25 | 20.7% | -219.8% | ||
| Q2 25 | 18.0% | -332.9% | ||
| Q1 25 | 22.4% | -687.9% | ||
| Q4 24 | 24.0% | — | ||
| Q3 24 | 21.1% | -63.1% | ||
| Q2 24 | 23.1% | -28.5% |
净利率ARYM
| Q1 26 | 17.0% | — | ||
| Q4 25 | 23.3% | -127.6% | ||
| Q3 25 | 19.3% | -263.8% | ||
| Q2 25 | 12.9% | -360.4% | ||
| Q1 25 | 18.9% | -302.2% | ||
| Q4 24 | 20.6% | 324.4% | ||
| Q3 24 | 17.9% | -964.4% | ||
| Q2 24 | 19.6% | -99.3% |
每股收益（稀释后）ARYM
| Q1 26 | $1.07 | — | ||
| Q4 25 | $1.53 | $-6.78 | ||
| Q3 25 | $1.18 | $-5.33 | ||
| Q2 25 | $0.75 | $-3.74 | ||
| Q1 25 | $1.11 | $-0.83 | ||
| Q4 24 | $1.23 | $-24.26 | ||
| Q3 24 | $0.97 | $-17.28 | ||
| Q2 24 | $1.05 | $-3.16 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.8B | $32.2M |
| 总债务越低越好 | $3.0B | $80.6M |
| 股东权益账面价值 | $6.9B | $13.0M |
| 总资产 | $12.8B | $106.7M |
| 负债/权益比越低杠杆越低 | 0.44× | 6.19× |
8季度趋势，按日历期对齐
现金及短期投资ARYM
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.8B | $32.2M | ||
| Q3 25 | $1.5B | — | ||
| Q2 25 | $1.5B | $41.0M | ||
| Q1 25 | $1.5B | $24.4M | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $1.8B | $267.0K | ||
| Q2 24 | $1.7B | $57.0K |
总债务ARYM
| Q1 26 | $3.0B | — | ||
| Q4 25 | $3.0B | $80.6M | ||
| Q3 25 | $3.4B | $90.6M | ||
| Q2 25 | $3.3B | $40.6M | ||
| Q1 25 | $3.3B | $10.6M | ||
| Q4 24 | $3.3B | — | ||
| Q3 24 | $2.1B | $6.2M | ||
| Q2 24 | $2.1B | $4.6M |
股东权益ARYM
| Q1 26 | $6.9B | — | ||
| Q4 25 | $6.7B | $13.0M | ||
| Q3 25 | $6.4B | $11.7M | ||
| Q2 25 | $6.1B | $21.0M | ||
| Q1 25 | $6.0B | $26.8M | ||
| Q4 24 | $5.9B | $28.1M | ||
| Q3 24 | $5.9B | $5.5M | ||
| Q2 24 | $6.2B | $8.5M |
总资产ARYM
| Q1 26 | $12.8B | — | ||
| Q4 25 | $12.7B | $106.7M | ||
| Q3 25 | $12.2B | $115.2M | ||
| Q2 25 | $12.2B | $69.5M | ||
| Q1 25 | $11.9B | $45.6M | ||
| Q4 24 | $11.8B | $54.0M | ||
| Q3 24 | $11.0B | $39.0M | ||
| Q2 24 | $10.9B | $39.4M |
负债/权益比ARYM
| Q1 26 | 0.44× | — | ||
| Q4 25 | 0.45× | 6.19× | ||
| Q3 25 | 0.53× | 7.73× | ||
| Q2 25 | 0.55× | 1.94× | ||
| Q1 25 | 0.56× | 0.40× | ||
| Q4 24 | 0.57× | — | ||
| Q3 24 | 0.36× | 1.13× | ||
| Q2 24 | 0.34× | 0.54× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $268.0M | $-3.0M |
| 自由现金流经营现金流 - 资本支出 | $175.0M | — |
| 自由现金流率自由现金流/营收 | 9.7% | — |
| 资本支出强度资本支出/营收 | 5.2% | — |
| 现金转化率经营现金流/净利润 | 0.88× | — |
| 过去12个月自由现金流最近4个季度 | $993.0M | — |
8季度趋势，按日历期对齐
经营现金流ARYM
| Q1 26 | $268.0M | — | ||
| Q4 25 | $545.0M | $-3.0M | ||
| Q3 25 | $362.0M | $-5.4M | ||
| Q2 25 | $221.0M | $-8.4M | ||
| Q1 25 | $431.0M | $-6.7M | ||
| Q4 24 | $481.0M | $-5.3M | ||
| Q3 24 | $452.0M | $-1.4M | ||
| Q2 24 | $333.0M | $-1.8M |
自由现金流ARYM
| Q1 26 | $175.0M | — | ||
| Q4 25 | $452.0M | — | ||
| Q3 25 | $259.0M | — | ||
| Q2 25 | $107.0M | — | ||
| Q1 25 | $334.0M | — | ||
| Q4 24 | $388.0M | — | ||
| Q3 24 | $360.0M | — | ||
| Q2 24 | $230.0M | $-1.8M |
自由现金流率ARYM
| Q1 26 | 9.7% | — | ||
| Q4 25 | 24.3% | — | ||
| Q3 25 | 14.9% | — | ||
| Q2 25 | 6.4% | — | ||
| Q1 25 | 19.9% | — | ||
| Q4 24 | 22.8% | — | ||
| Q3 24 | 22.8% | — | ||
| Q2 24 | 14.6% | -61.2% |
资本支出强度ARYM
| Q1 26 | 5.2% | — | ||
| Q4 25 | 5.0% | — | ||
| Q3 25 | 5.9% | — | ||
| Q2 25 | 6.8% | — | ||
| Q1 25 | 5.8% | — | ||
| Q4 24 | 5.5% | — | ||
| Q3 24 | 5.8% | — | ||
| Q2 24 | 6.5% | 0.1% |
现金转化率ARYM
| Q1 26 | 0.88× | — | ||
| Q4 25 | 1.26× | — | ||
| Q3 25 | 1.08× | — | ||
| Q2 25 | 1.03× | — | ||
| Q1 25 | 1.36× | — | ||
| Q4 24 | 1.37× | — | ||
| Q3 24 | 1.60× | — | ||
| Q2 24 | 1.08× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
A
| Service Other | $525.0M | 29% |
| Chemicaland Energy Market | $422.0M | 23% |
| Agilent Cross Lab | $273.0M | 15% |
| Environmentaland Forensics Market | $177.0M | 10% |
| Food Market | $166.0M | 9% |
| Academiaand Government Market | $130.0M | 7% |
| Applied Markets | $98.0M | 5% |
RYM
| Nonlicensing Revenue | $9.5M | 89% |
| Cultivation Business Discontinued Operations | $1.2M | 11% |
